IB05204, a dichloropyridodithienotriazine, inhibits angiogenesis in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 6, Issue 10, 2007, Pages 2675-2685

  Martínez Poveda, Beatriz ^a   Muñoz Chápuli, Ramón ^a   Rodríguez Nieto, Salvador ^b   Quintela, José M ^c   Fernández, Antonio ^d   Medina, Miguel Ángel ^a   Quesada, Ana R ^a,e  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF A CORUÑA   (Spain)

^d Instituto Biomar SA   (Spain)

^e Facultad de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4,8 DICHLORO 12 PHENYLPYRIDO[5',6':4'',5'':3',2':4,5]DITHIENO[3'',2'':3,2] 1,2,3 DITRIAZINE; ANGIOGENESIS INHIBITOR; CASPASE; CYCLOOXYGENASE 2; CYTOCHROME C; DICHLOROPYRIDODITHIENOTRIAZINE; GELATINASE A; IB 05204; PROTEIN KINASE B; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL SURVIVAL; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE MIGRATION INHIBITION TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ALLANTOIS; ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CATTLE; CELL DIFFERENTIATION; CELL MOVEMENT; CHICK EMBRYO; CHORION; COLLAGEN; COLONIC NEOPLASMS; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FIBROSARCOMA; FLOW CYTOMETRY; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 2; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; TRIAZINES;

EID: 35848937161     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0136     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
3. Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006;26:483-530.
4. Quintela JM, Peinador C, Botana L, Estévez M, Riguera R. Synthesis and antihistaminic activity of 2-guanadino-3-cyanopyridines and pyrido[2,3-d]-pyrimidines. Bioorg Med Chem 1997;5:1543-53.
5. Garrido T, Riese HH, Aracil M, Pérez-Aranda A. Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: a modified chemotaxis chamber assay. Br J Cancer 1995;71:770-5.
6. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988;107:1589-98.
7. Rodríguez-Nieto S, González-Iriarte M, Carmona R, Muñoz-Chápuli R, Medina MA, Quesada AR. Anti-angiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J 2002;16:261-3.
8. Rodríguez-Nieto S, Medina MA, Quesada AR. A re-evaluation of fumagillin selectivity towards endothelial cells. Anticancer Res 2001;21:3457-60.
9. Fajardo I, Díez E, Rodríguez-Nieto S, et al. Effects of genistein and 2-methoxyestradiol on matrix metalloproteinases and their inhibitors secreted by Ehrlich ascites tumor cells. Anticancer Res 2000;20:1691-4.
10. Martínez-Poveda B, Quesada AR, Medina MA. Hypericin in the dark inhibits key steps of angiogenesis in vitro. Eur J Pharmacol 2005;516:97-103.
11. Fajardo I, Urdiales JL, Sánchez-Jiménez F, Medina MA. An experiment on apoptosis induced by polyamine adducts produced in the presence of serum amine oxidase. Biochem Educ 2000;28:110-2.
12. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
13. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40.
14. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001;15:1798-800.
15. Lamy S, Blanchette M, Michaud-Levesque J, et al. Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis 2006;27:989-96.
16. Castro ME, González-Iriarte M, Barrero AF, et al. Study of puupehenone and related compounds as inhibitors of angiogenesis. Int J Cancer 2004;110:31-8.
17. Martínez-Poveda B, Quesada AR, Medina MA. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Int J Cancer 2005;117:775-80.
18. Cárdenas C, Quesada AR, Medina MA. Evaluation of the antiangiogenic effect of aloe-emodin. Cell Mol Life Sci 2006;63:3083-9.
19. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-8.
20. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
21. Patyna S, Laird AD, Mendel DB, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5:1774-82.
22. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
23. Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006;66:9134-42.
24. Wissner A, Floyd MB, Johnson BD, et al. 2-(Quinazolin-4-ylamino)-[1,4] benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. J Med Chem 2005;48:7560-81.
25. Kuo GH, Prouty C, Wang A, et al. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 2005;48:4892-909.
26. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001;33:960-70.
27. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000;97:3884-9.
28. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-46.
29. Philip S, Kundu GC. Osteopontin induces nuclear factor κB-mediated promatrix metalloproteinase-2 activation through IκBα/IKK signalling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003;278:14487-97.
30. Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000;14:2477-85.
31. Iñiguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003;9:73-8.
32. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-92.
33. Yang X, Sheares KK, Davie N, et al. Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2002;27:688-96.
34. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31.
35. Colleselli D, Bijuklic K, Mosheimer BA, Kahler CM. Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Exp Cell Res 2006;312:2933-41.
36. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 2004;68:341-50.
37. Somanath PR, Razorenova OV, Chen J, Byzova TV. Free in PMC Akt1 in endothelial cell and angiogenesis. Cell Cycle 2006;5:512-8.
38. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
39. González-Iriarte M, Carmona R, Pérez-Pomares JM, et al. A modified chorioallantoic membrane assay allows for specific detection of endothelial apoptosis induced by antiangiogenic substances. Angiogenesis 2003;6:251-4.
40. Hanford HA, Wong CA, Kassan H, et al. Angiostatin 4.5-mediated apoptosis of vascular endothelial cells. Cancer Res 2003;63:4275-80.
41. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003;278:37632-6.
42. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101:2476-81.
43. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003;13:159-67.
44. Lawen A. Apoptosis - an introduction. Bioessays 2003;25:888-96.
45. Oancea M, Mazumder S, Crosby ME, Almasan A. Apoptosis assays. Methods Mol Med 2006;29:279-90.
46. Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough. Limitations and future of the antiangiogenic treatment of cancer. BioEssays. In press 2007.
47. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;15:725-31.